Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$334M Sell
5,998,486
-254,237
-4% -$13.8M 0.01% 709
2025
Q4
$309M Sell
6,252,723
-369,228
-6% -$17.2M 0.01% 739
2025
Q3
$289M Sell
6,621,951
-92,272
-1% -$3.6M 0.01% 757
2025
Q2
$261M Sell
6,714,223
-258,775
-4% -$9.89M 0.01% 767
2025
Q1
$273M Sell
6,972,998
-52,095
-0.7% -$1.91M 0.01% 725
2024
Q4
$240M Buy
7,025,093
+247,172
+4% +$8.9M 0.01% 831
2024
Q3
$280M Sell
6,777,921
-24,359
-0.4% -$997K 0.01% 735
2024
Q2
$264M Sell
6,802,280
-156,671
-2% -$6.59M 0.01% 719
2024
Q1
$301M Sell
6,958,951
-94,039
-1% -$3.88M 0.01% 680
2023
Q4
$264M Sell
7,052,990
-5,049
-0.1% -$181K 0.01% 705
2023
Q3
$258M Sell
7,058,039
-186,654
-3% -$6.62M 0.01% 658
2023
Q2
$261M Sell
7,244,693
-185,820
-3% -$6.67M 0.01% 672
2023
Q1
$267M Buy
7,430,513
+9,173
+0.1% +$321K 0.02% 659
2022
Q4
$263M Sell
7,421,340
-145,221
-2% -$4.84M 0.02% 657
2022
Q3
$225M Buy
7,566,561
+760,637
+11% +$28.8M 0.01% 692
2022
Q2
$373M Sell
6,805,924
-389,999
-5% -$21.5M 0.02% 552
2022
Q1
$397M Sell
7,195,923
-10,458
-0.1% -$568K 0.02% 603
2021
Q4
$402M Sell
7,206,381
-56,847
-0.8% -$2.96M 0.02% 594
2021
Q3
$352M Sell
7,263,228
-67,410
-0.9% -$3.39M 0.02% 615
2021
Q2
$370M Sell
7,330,638
-168,477
-2% -$8.1M 0.02% 625
2021
Q1
$340M Sell
7,499,115
-109,161
-1% -$4.95M 0.02% 611
2020
Q4
$355M Buy
7,608,276
+96,090
+1% +$4.41M 0.02% 573
2020
Q3
$358M Buy
7,512,186
+58,485
+0.8% +$2.93M 0.02% 516
2020
Q2
$384M Buy
7,453,701
+155,301
+2% +$7.97M 0.03% 494
2020
Q1
$351M Buy
7,298,400
+999
+0% +$53.3K 0.03% 457
2019
Q4
$433M Sell
7,297,401
-243,377
-3% -$13.5M 0.03% 498
2019
Q3
$407M Sell
7,540,778
-220,146
-3% -$11.3M 0.03% 498
2019
Q2
$393M Sell
7,760,924
-15,579
-0.2% -$782K 0.03% 510
2019
Q1
$412M Sell
7,776,503
-130,209
-2% -$6.51M 0.03% 477
2018
Q4
$382M Sell
7,906,712
-40,174
-0.5% -$1.98M 0.03% 456
2018
Q3
$399M Sell
7,946,886
-53,132
-0.7% -$2.7M 0.03% 488
2018
Q2
$403M Sell
8,000,018
-89,597
-1% -$4.51M 0.03% 470
2018
Q1
$395M Sell
8,089,615
-119,791
-1% -$5.58M 0.03% 475
2017
Q4
$364M Sell
8,209,406
-40,842
-0.5% -$1.89M 0.03% 506
2017
Q3
$419M Sell
8,250,248
-19,038
-0.2% -$966K 0.04% 457
2017
Q2
$446M Sell
8,269,286
-123,753
-1% -$6.6M 0.04% 435
2017
Q1
$442M Sell
8,393,039
-87,624
-1% -$4.45M 0.04% 438
2016
Q4
$408M Buy
8,480,663
+144,454
+2% +$7.14M 0.04% 439
2016
Q3
$449M Sell
8,336,209
-41,887
-0.5% -$2.3M 0.05% 397
2016
Q2
$454M Buy
8,378,096
+89,079
+1% +$4.69M 0.05% 382
2016
Q1
$420M Buy
8,289,017
+19,398
+0.2% +$966K 0.05% 399
2015
Q4
$417M Sell
8,269,619
-46,800
-0.6% -$2.39M 0.05% 394
2015
Q3
$400M Sell
8,316,419
-81,902
-1% -$4.26M 0.05% 388
2015
Q2
$437M Sell
8,398,321
-130,149
-2% -$7.33M 0.05% 380
2015
Q1
$492M Sell
8,528,470
-46,231
-0.5% -$2.65M 0.05% 368
2014
Q4
$458M Sell
8,574,701
-60,294
-0.7% -$3.37M 0.05% 394
2014
Q3
$496M Sell
8,634,995
-13,001
-0.2% -$797K 0.05% 350
2014
Q2
$578M Sell
8,647,996
-57,643
-0.7% -$3.9M 0.06% 318
2014
Q1
$581M Sell
8,705,639
-31,659
-0.4% -$2.14M 0.07% 304
2013
Q4
$583M Sell
8,737,298
-106,492
-1% -$6.91M 0.06% 314
2013
Q3
$555M Sell
8,843,790
-116,701
-1% -$7.51M 0.07% 307
2013
Q2
$560M Buy
+8,960,491
New +$569M 0.07% 281

Other funds holding GSK

State Street's GSK Position: Q1 2026 in Review

State Street reduced its GSK (GSK) stake by 4.1% in Q1 2026, selling an estimated $13.8M and leaving 5,998,486 shares worth $334M. The position accounts for 0.01% of the portfolio, ranked #709.

State Street first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $583M in Q4 2013. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • State Street held 5,998,486 shares of GSK worth $334M as of Q1 2026.
  • State Street sold 254,237 GSK shares in Q1 2026, an estimated $13.8M.
  • GSK made up 0.01% of State Street's portfolio in Q1 2026, its #709 holding.
  • State Street first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • State Street's GSK position peaked at $583M in Q4 2013.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.